MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Trading 03-19 10:36:14 EDT

1.46

-0.03

-2.35%

High1.49	Low1.43	Vol111.86K
Open1.46	D1 Closing1.49	Amplitude4.03%
Mkt Cap85.35M	Tradable Cap41.23M	Total Shares58.66M
T/O161.91K	T/O Rate0.39%	Tradable Shares28.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.455,"timestamp":1773930948218,"preClose":1.49,"halted":0,"volume":111859,"delay":0,"changeRate":-0.023489932885905986,"floatShares":28340000,"shares":58659600,"eps":-0.768287,"marketStatus":"Trading","change":-0.035,"latestTime":"03-19 10:36:14 EDT","open":1.46,"high":1.49,"low":1.43,"amount":161913.6429482,"amplitude":0.040268,"askPrice":1.47,"askSize":1400,"bidPrice":1.44,"bidSize":1820,"shortable":3,"etf":0,"ttmEps":-0.768287,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773950400000},"marketStatusCode":2,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.49,"preHourTrading":{"tag":"盘前","latestPrice":1.4891,"preClose":1.49,"latestTime":"09:26 EDT","volume":2536,"amount":3730.459804,"timestamp":1773926816134,"change":-0.0009,"changeRate":-0.000604,"amplitude":0.020134},"postHourTrading":{"tag":"盘后","latestPrice":1.46,"preClose":1.49,"latestTime":"19:38 EDT","volume":2545,"amount":3738.2273,"timestamp":1773877083993,"change":-0.03,"changeRate":-0.020134,"amplitude":0.020134},"volumeRatio":0.995747},"requestUrl":"/m/hq/s/MAIA/wiki","defaultTab":"wiki","newsList":[{"id":"2617560989","title":"MAIA Biotechnology Completes $30 Million Public Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617560989","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617560989?lang=en_us&edition=fundamental","pubTime":"2026-03-05 07:36","pubTimestamp":1772667409,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an update. On March 2, 2026, MAIA Biotechnology, Inc. entered into an underwriting agreement with K...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-completes-30-million-public-stock-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-completes-30-million-public-stock-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2617627525","title":"BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617627525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617627525?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:41","pubTimestamp":1772664118,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC FilingMarch 4  - SEC Filing:MAIA BIOTECHNOLOGY INC - ON MARCH 2, CO ENTERS UNDERWRITING AGREEMENT WITH KONIK CAPITAL PARTNERS ON MARCH 2, 2026 - SEC FILINGMAIA BIOTECHNOLOGY INC - TO ISSUE 20,000,000 SHARES OF COMMON STOCK IN PUBLIC OFFERING - SEC FILINGSource text: [ID:n0001493152-26-008897]Further company coverage: MAIA.A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2617625355","title":"Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617625355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617625355?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:23","pubTimestamp":1772663005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2617539562","title":"Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617539562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617539562?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:23","pubTimestamp":1772663005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2617569689","title":"MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569689","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569689?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:00","pubTimestamp":1772658000,"startTime":"0","endTime":"0","summary":"Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March  04, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249706/0/en/MAIA-Biotechnology-Announces-Closing-of-30-Million-Underwritten-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2616934666","title":"BUZZ-MAIA Biotechnology plunges after $30 million share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2616934666","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616934666?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:38","pubTimestamp":1772534337,"startTime":"0","endTime":"0","summary":"BUZZ-MAIA Biotechnology plunges after $30 million share sale** Drug developer MAIA Biotechnology's MAIA.A shares plunge 29% to $1.47 premarket** MAIA late on Monday announced pricing of $30 million public offering** Co sold 20 million shares at $1.50 apiece, a 27.5% discount to stock's last close     ** Offering led by healthcare-dedicated investors alongside existing shareholders - MAIA ** Proceeds will be used to conduct clinical trials and for working capital, general purposes** Konik Capital Partners was sole book-running manager for offering** MAIA had 38.7 million outstanding shares as of March 2, according to offering prospectus** Lone analyst covering MAIA rates it \"buy\" and has $12.14 PT - data compiled by LSEG** As of last close, MAIA stock up 35.3% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4N3ZQ1F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-MAIA Biotechnology plunges after $30 million share sale","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2616534645","title":"MAIA Biotechnology 20M share Spot Secondary priced at $1.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2616534645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616534645?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:20","pubTimestamp":1772533212,"startTime":"0","endTime":"0","summary":"acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-20m-share-spot-secondary-priced-at-1-50-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-20m-share-spot-secondary-priced-at-1-50-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2616233364","title":"MAIA Biotechnology announces common stock offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2616233364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616233364?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:06","pubTimestamp":1772489216,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stoc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-common-stock-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-common-stock-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2616646633","title":"MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2616646633","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616646633?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:00","pubTimestamp":1772488800,"startTime":"0","endTime":"0","summary":"CHICAGO, IL, March  02, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247913/0/en/MAIA-Biotechnology-Announces-Proposed-Underwritten-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2616353810","title":"Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616353810?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:10","pubTimestamp":1772460635,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurinia Pharmaceuticals (AUPH – Research Report), MAIA Biotechnol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-aurinia-pharmaceuticals-auph-maia-biotechnology-inc-maia-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-aurinia-pharmaceuticals-auph-maia-biotechnology-inc-maia-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4135","CGON","LU0128526141.USD","AUPH","CG","BK4585","LU0029874061.USD","IE00B64PRP62.GBP","BK4588","BK4581","HCSG","BK4137","MAIA","XBI","LABU","BK4139","XLV"],"gpt_icon":0},{"id":"2613871781","title":"MAIA Biotechnology published a 2026 Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613871781?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:50","pubTimestamp":1771941043,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-published-a-2026-letter-to-shareholders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-published-a-2026-letter-to-shareholders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2613271292","title":"Maia Biotechnology Publishes February 2026 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2613271292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613271292?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:46","pubTimestamp":1771940769,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. published a 2026 shareholder letter highlighting updates on ateganosine  clinical development in non-small cell lung cancer. The letter cites interim Phase 2 THIO-101 results of 88% disease control rate, 38% overall response rate, and 17.8 months median overall survival, and notes FDA Fast Track designation granted in July 2025. The letter also states Phase 3 THIO-104 is underway with up to 300 patients planned and indicates Phase 2 THIO-101 Part C is nearing completion with a potential accelerated approval pathway. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief on Febru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5TdhBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2613871297","title":"Maia Biotechnology Announces Availability of 2026 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613871297?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:45","pubTimestamp":1771940714,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Announces Availability of 2026 Shareholder Letter               Maia Biotechnology Inc. announced that its 2026 Letter to Shareholders is now available at ir.maiabiotech.com.       ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7Cl5F7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","BK4588","MAIA","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4112","IE00B64PRP62.GBP","BK4139","SG9999014039.USD"],"gpt_icon":0},{"id":"2613971013","title":"MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2613971013","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613971013?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:45","pubTimestamp":1771940700,"startTime":"0","endTime":"0","summary":"Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243622/0/en/MAIA-Biotechnology-s-Phase-3-Momentum-Demonstrates-Potential-Breakthrough-Anticancer-Opportunity-in-50-Billion-Immunotherapy-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4585","BK4588","LU0053666078.USD","L","LU2487616109.SGD","LU0210528500.USD","BK4107","BK4139","CPI"],"gpt_icon":0},{"id":"2605142385","title":"MAIA Biotechnology outlines 2026 goals for ateganosine program","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142385?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:04","pubTimestamp":1768946697,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an update. On January 20, 2026, MAIA Biotechnology reported on its 2025 progress and set out key cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-outlines-2026-goals-for-ateganosine-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-outlines-2026-goals-for-ateganosine-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2604485112","title":"MAIA Biotechnology highlights milestones, catalysts for FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2604485112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604485112?lang=en_us&edition=fundamental","pubTime":"2026-01-20 23:25","pubTimestamp":1768922723,"startTime":"0","endTime":"0","summary":"Targeted 2026 Milestones: Initial measures of efficacy from Phase 3 study. Interim disease control rates, overall response rates and progression fr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-highlights-milestones-catalysts-for-fy26-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-highlights-milestones-catalysts-for-fy26-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2604114054","title":"Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine","url":"https://stock-news.laohu8.com/highlight/detail?id=2604114054","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604114054?lang=en_us&edition=fundamental","pubTime":"2026-01-20 23:15","pubTimestamp":1768922110,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. announced a business update highlighting key achievements in 2025 and outlining targeted milestones for 2026. The company reported strong clinical execution in 2025, delivering efficacy data for ateganosine, its telomere-targeting anticancer agent, sequenced with a checkpoint inhibitor in third-line non-small cell lung cancer . Results showed disease control, response rates, and survival data exceeding standard of care benchmarks. Ateganosine received FDA Fast Track designation in 2025, supporting concurrent Phase 2 and Phase 3 trials and positioning the drug for potential Accelerated Approval and Priority Review. Maia Biotechnology also established combination partnerships with Roche for atezolizumab and BeOne Medicines for tislelizumab. The company raised approximately $17.6 million in capital during 2025, with board members participating in nearly all transactions. As of December 31, 2025, directors and officers collectively hold more than 5 million shares, r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL2pNhYc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","BK4139","BK4112","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","MAIA"],"gpt_icon":0},{"id":"2603850656","title":"MAIA Biotechnology Highlights Strategy in New Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603850656","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603850656?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:48","pubTimestamp":1768344530,"startTime":"0","endTime":"0","summary":"An update from MAIA Biotechnology, Inc. ( ($MAIA) ) is now available. On January 13, 2026, MAIA Biotechnology, Inc. filed and published a set of in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-strategy-in-new-investor-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-strategy-in-new-investor-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2602543866","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543866","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543866?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:44","pubTimestamp":1768225499,"startTime":"0","endTime":"0","summary":"Stan Smith, Director of Maia Biotechnology Inc., reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL79tlWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2593147221","title":"MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings","url":"https://stock-news.laohu8.com/highlight/detail?id=2593147221","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593147221?lang=en_us&edition=fundamental","pubTime":"2025-12-24 21:01","pubTimestamp":1766581260,"startTime":"0","endTime":"0","summary":"Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.  24, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/24/3210313/0/en/MAIA-Biotechnology-Board-Members-Continue-to-Participate-in-Private-Placement-Financings.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0210528500.USD","BK4585","LU2487616109.SGD","BK4107","LU0053666078.USD","BK4139","MAIA","L"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maiabiotech.com","stockEarnings":[{"period":"1week","weight":-0.051},{"period":"1month","weight":-0.224},{"period":"3month","weight":0.2417},{"period":"6month","weight":-0.0387},{"period":"1year","weight":-0.1078},{"period":"ytd","weight":-0.0261}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.06082},{"month":3,"riseRate":0.25,"avgChangeRate":-0.016833},{"month":4,"riseRate":0.666667,"avgChangeRate":0.190738},{"month":5,"riseRate":0.666667,"avgChangeRate":0.134126},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.131471},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058081},{"month":8,"riseRate":0,"avgChangeRate":-0.148704},{"month":9,"riseRate":0.25,"avgChangeRate":0.000086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}